Skip to main content


Fig. 3 | Cell & Bioscience

Fig. 3

From: Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

Fig. 3

pNGVL4a-Sig/E7(detox)/HSP70 DNA priming followed by TA-CIN boost through either i.d or i.m. injection generated robust HPV16 E7-specific CD8+ T cell response in TC-1 tumor-bearing mice. Five to eight weeks old female C57BL/6 mice (5 mice/group) were injected with 5 × 104 of TC-1 cells subcutaneously on day 0. The mice were vaccinated with either 25 μg/mouse of pNGVL4a-Sig/E7(detox)/HSP70 DNA in 50 μl via intramuscular injection (leg muscle) or TA-CIN with indicated dose in 20 μl via i.d. or i.m. injection. The mice were boosted as indicated twice with 1-week interval. Six days after last vaccination, PBMCs were prepared and stained with anti-mouse CD8 and HPV16 E7 tetramer. The data were acquired with FACSCalibur and analyzed with CellQuest. a Schematic illustration of the experiment. b and c Flow cytometry analysis of HPV16 E7-specific CD8+ T cells in peripheral blood induced by pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN vaccination

Back to article page